S&P 500 Industrials Sector SEC Filings — May 07, 2026

07-05-2026

Ligand Pharmaceuticals reported Q1 2026 total revenues of $51.7 million, up 14% YoY from $45.3 million, driven by strong 56% YoY royalty revenue growth to $43.0 million from Filspari, Ohtuvayre, and Capvaxive; however, Captisol sales declined to $8.7 million from $13.5 million due to customer order timing, and GAAP net loss widened to $13.3 million from a prior-year loss of $42.5 million amid a $49.2 million non-cash loss on Pelthos investment. Adjusted net income grew 30% YoY to $34.6 million ($1.63 per diluted share), cash position strengthened to $779.4 million, and the company reaffirmed raised full-year 2026 guidance including royalty revenue of $225-250 million while providing updates on the pending XOMA Royalty acquisition expected to close in Q3 2026.

• ·R&D expenses $2.1M in Q1 2026 vs $50.1M in Q1 2025 (prior year included $44.3M one-time charge)
• ·G&A expenses increased to $20.8M from $18.8M YoY due to higher headcount and share-based compensation
• ·Non-operating expense net $41.6M in Q1 2026 vs $14.0M (driven by $49.2M non-cash loss on Pelthos investment)
• ·2026 guidance: Adjusted EPS $8.50-$9.50; Captisol revenue $35-40M; Contract revenue $10-20M
• ·XOMA acquisition adds >120 assets including 7 commercial and 14 late-stage programs; funded by cash and revolver; annual capital deployment $150-250M
• ·Filspari U.S. net sales $105M in Q1 2026 per Travere (+88% YoY); FDA approval for FSGS on April 13, 2026

07-05-2026

Target Hospitality Corp. (Nasdaq: TH) announced the appointment of Paul Hohnsbeen as an independent director to its Board of Directors, effective May 5, 2026, with membership on the Nominating and Corporate Governance Committee. Mr. Hohnsbeen brings over three decades of expertise in data centers, real estate development, construction, energy infrastructure, and AI-enabled workflows, particularly from roles at Aligned Data Centers, Equinix, and others. The appointment supports Target's strategic growth in high-value end markets like AI-driven data centers, as stated by CEO Brad Archer.

• ·Mr. Hohnsbeen's career highlights: COO at Aligned Data Centers (since 2022), VP IBX Operations EMEA at Equinix (2016-2021), Director Business Strategy at Laing O’Rourke (2013-2015), Group COO at Global Switch (2010-2012), Executive Program Director at KEO International Consultants (2009-2010), various executive roles at Lehman Brothers (2002-2008), and senior roles at Deutsche Bank, Morgan Stanley, Gregotti Associati International, and Skidmore, Owings & Merrill.
• ·Bachelor of Arts in Architecture from University of California, Berkeley.
• ·Investor contact: Mark Schuck, (832) 702-8009, ir@targethospitality.com

07-05-2026

Unity Forge Inc, a Wyoming-incorporated development-stage IT services company founded June 20, 2025, filed S-1/A Amendment No. 2 to register 5,000,000 shares of common stock at $0.04 per share in a self-underwritten, best-efforts IPO to raise up to $200,000 over 240 days. For the six months ended March 31, 2026, it reported revenue of $22,675, gross profit of $14,000, and net income of $3,731 with cash balance of $11,668, reflecting initial operations including two customer agreements. However, the company has limited history, requires $50,000 minimum funding for the next 12 months, and its auditor raised substantial doubt about its ability to continue as a going concern.

• ·Incorporated June 20, 2025 in Wyoming; principal office in Podgorica, Montenegro.
• ·Website launched: www.unity-forge.com.
• ·First customer IT Services Agreement signed August 20, 2025.
• ·Emerging growth company under JOBS Act; not a blank check company.
• ·No underwriters or broker-dealers; CEO to sell shares under Rule 3a4-1 safe harbor.
• ·Plans to seek market maker for OTC quotation post-effective date, but no assurance of market development.
• ·If fewer than 2,384,000 shares sold, CEO retains majority ownership.

07-05-2026

BridgeBio Pharma reported strong Q1 2026 total revenues of $194.5 million, up 67% YoY from $116.6 million, primarily driven by Attruby net product revenue surging to $180.6 million from $36.7 million. However, total operating costs and expenses increased 36% to $300.5 million from $221.0 million, reflecting higher SG&A and R&D investments, resulting in a net loss of $164.0 million, slightly narrowed from $167.4 million YoY. The company held $940.2 million in cash, cash equivalents, and marketable securities as of March 31, 2026, up significantly from $587.5 million at year-end 2025, and authorized a $500 million share repurchase program.

• ·NDA submitted to FDA for BBP-418 in LGMD2I/R9; on track for encaleret NDA in 1H 2026 and infigratinib NDA in Q3 2026, all potentially eligible for priority review.
• ·Brazilian approval for BEYONTTRA™ (acoramidis) on May 4, 2026.
• ·Attruby showed 44.7% reduction in all-cause mortality and 49.3% in cardiovascular mortality through Month 54 in open-label extension.
• ·Real-world evidence: Attruby reduces diuretic intensification by 43% vs tafamidis; statistically significant outcome improvements vs tafamidis.

07-05-2026

Entergy Corporation entered into forward sale agreements on May 5, 2026, with Wells Fargo Bank, Citibank, N.A., Barclays Bank PLC, and The Bank of Nova Scotia for an aggregate of 19,247,788 shares of common stock at an initial forward sale price of $110.74 per share, with settlement at the company's election on or prior to April 30, 2028. In connection, forward sellers sold these borrowed shares via an underwriting agreement with representatives including Wells Fargo Securities, LLC, granting an option for an additional 2,887,168 shares; the offering closed on May 7, 2026. Physical or net share settlement may result in dilution to earnings per share, while cash settlement could involve payments based on market price versus forward price.

• ·Forward sale price subject to daily adjustments based on overnight bank funding rate less a spread, and decreases on specified dates.
• ·Forward purchasers may accelerate settlement under certain circumstances, including borrowing difficulties, excess dividends, ownership thresholds, extraordinary events, or defaults.

07-05-2026

Codexis reported Q1 2026 total revenues of $15.2 million, up 102% YoY from $7.5 million, driven by $8.1 million in R&D revenue including from the Merck agreement, with product gross margin improving to 71% from 55%. R&D expenses decreased 12% to $11.4 million and SG&A fell 21% to $9.8 million, narrowing net loss to $8.7 million ($0.10/share) from $20.7 million ($0.25/share); however, cash and equivalents plus short-term investments declined to $65.1 million from $78.2 million at year-end 2025. The company reiterated FY2026 revenue guidance of $72-76 million and cash runway through 2027, alongside business highlights like ISO 9001 certification and upcoming TIDES USA presentations on ECO Synthesis platform.

• ·Received ISO 9001 certification for in-house manufacturing suite.
• ·Supported enzyme for pharma biocatalysis product that received FDA approval post-Phase 3, bringing total to 13 licensed branded products.
• ·Agreed to supply 50g of siRNA using ECO Synthesis for pre-IND studies.
• ·TIDES USA annual meeting presentations May 11-14, 2026, in Boston.
• ·Building permit application planned for Q2 2026 for ECO GMP center; full production by end-2027.

07-05-2026

Genpact reported first quarter 2026 net revenues of $1.296 billion, up 6.7% year-over-year, propelled by Advanced Technology Solutions net revenues of $345 million (up 24.3% YoY, 27% of total), while Core Business Services net revenues of $951 million grew modestly by 1.4% YoY. Gross profit rose 9.9% to $472 million with a 36.4% margin, marking the 12th consecutive quarter of YoY expansion, diluted EPS increased 17.8% to $0.86, and adjusted diluted EPS rose 16.7% to $0.98; however, operating cash flow was a use of $24 million versus $40 million generated in Q1 2025. The company repurchased 1.8 million shares for $70 million and provided outlook for at least 7% FY2026 net revenue growth and over 10% adjusted diluted EPS growth.

• ·Cash and cash equivalents decreased to $578 million as of March 31, 2026 from $854 million as of December 31, 2025.
• ·Q2 2026 net revenue outlook: $1.324B to $1.336B (5.5%-6.5% YoY growth).
• ·FY2026 net revenue growth outlook: at least 7% as reported (6.8% constant currency), with Advanced Technology Solutions at least 20% growth.
• ·Adjusted diluted EPS outlook: Q2 $0.96-$0.97; FY2026 growth >10%.

07-05-2026

Ocugen, Inc. completed a private offering of $115.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034, generating net proceeds of approximately $99.5 million after discounts and expenses. The company used $32.7 million of the net proceeds to fully repay the outstanding principal, accrued interest, prepayment fee, and expenses under the Avenue Loan Agreement, terminating that agreement. As-adjusted cash, cash equivalents, and restricted cash as of March 31, 2026, is estimated at $99.0 million for general corporate purposes.

• ·Notes mature on May 15, 2034; interest payable semi-annually starting November 15, 2026.
• ·Conversion not permitted before earliest of May 15, 2027 or reserved share effective date; initially cash settlement only until reserved share effective date.
• ·Company may redeem notes for cash on or after May 15, 2029 if stock price >=130% of conversion price for specified period.
• ·Holders may require repurchase on May 15, 2032 or upon fundamental change.
• ·Events of default include payment defaults, conversion failures, cross-defaults on >$10.0M indebtedness, and bankruptcy events.

07-05-2026

Designer Brands Inc. (DBI) filed its DEF 14A Proxy Statement on May 7, 2026, for the virtual 2026 Annual Meeting of Shareholders on June 17, 2026 (record date April 23, 2026), proposing election of four Class I directors to serve until 2029, ratification of Deloitte & Touche LLP as FY2026 auditors, advisory approval of FY2025 named executive officer compensation, and multiple amendments to the Code of Regulations including enhanced advance notice procedures and voting standard changes. CEO Douglas M. Howe noted FY2025 progress in business transformation, including elevated assortment, inventory productivity gains, a new DSW brand positioning campaign, and Brand Portfolio profitability improvements despite tariff challenges, alongside FY2026 organizational changes and new CFO Sheamus Toal appointment. No quantitative declines or flat metrics were disclosed.

• ·2026 Annual Meeting: June 17, 2026 at 1:00 p.m. ET, virtual-only at www.virtualshareholdermeeting.com/DBI2026
• ·Voting: One vote per Class A share, eight votes per Class B share
• ·Proxy materials distributed beginning May 7, 2026, including 2025 Form 10-K

07-05-2026

Abacus Global Management reported strong Q1 2026 results with total revenue up 35% YoY to $59.4M, adjusted net income up 17% to $20.1M, adjusted EBITDA up 33.3% to $32.7M, and operating cash flow of $91.7M versus negative $61.6M prior year; longevity income funds AUM grew nearly 4x YoY to ~$1B while gross AUM reached $3.6B. However, life settlement policies held declined to 659 from 753 YoY, life settlement policies at fair value dropped to $392.8M from $468.9M at year-end, and total assets decreased to $829.8M from $902.2M. The company raised FY2026 adjusted net income guidance to $100–$106M (up to 24% YoY) and announced a $53M minority stake acquisition in Manning & Napier, expected to close Q2 2026.

• ·Announced leadership changes post-quarter: Alexei Solomon elevated to Chief Accounting Officer, Elena Plesco named CIO, Samantha Butcher to Executive Officer, Bill McCauley to COO.
• ·Board approved additional $20M share repurchases in January 2026.
• ·Returned 100% of investor capital in LMA Income II Fund at term, with two-thirds recommitting or extending.
• ·Annualized turnover ratio 1.9x (within 1.5x-2.0x target); average realized gain 26% (exceeds 20% target).
• ·Cash and equivalents $37.2M; total assets $829.8M as of Mar 31, 2026.

07-05-2026

Eloxx Pharmaceuticals, Inc. filed an IPO registration statement on 2026-05-07 (AccNo: 0001193125-26-212324, Size: 2 MB), marking the initial S-1 filing stage where SEC review typically begins within 30 days. No financial highlights, revenue, pricing range, shares offered, risks, or use of proceeds are disclosed in the provided information. Sector is not specified, limiting business and competitive assessment.

• ·Event Type: IPO Registration
• ·Date: 2026-05-07
• ·Source: us_sec
• ·Sector: not specified
• ·Current IPO stage: S-1 filed, SEC review begins (typically 30 days); next milestones NOT_DISCLOSED

07-05-2026

Jade Biosciences, Inc. (JBIO), a clinical-stage biopharmaceutical company developing biologic therapies for autoimmune diseases including lead candidate JADE101 for IgA nephropathy, JADE201 targeting BAFF-R, and JADE301, filed an S-3 shelf registration statement on May 7, 2026, to register securities for potential future offerings. The filing incorporates recent SEC reports such as the 10-K for year ended December 31, 2025, 10-Q for Q1 2026, and 8-Ks from April 2026, and details corporate history including the April 28, 2025 merger with Aerovate Therapeutics and redomestication to Nevada. No financial performance metrics or period-over-period comparisons are provided in the filing.

• ·Principal executive offices: 221 Crescent St., Building 23, Suite 105, Waltham, MA 02453; telephone: (781) 312-3013.
• ·Originally incorporated as Aerovate Therapeutics, Inc. on July 27, 2018; merger agreement dated October 30, 2024; closing and redomestication effective April 28, 2025.
• ·No cash dividends declared or paid; intends to retain earnings for operations.
• ·Classified board of directors with three classes; directors elected for three-year terms.

07-05-2026

07-05-2026

07-05-2026

07-05-2026

07-05-2026

SurgePays, Inc. (SURG) filed a DEF 14A proxy statement dated May 07, 2026, for its 2026 annual meeting of stockholders, seeking shareholder approval to elect four director nominees (Kevin Brian Cox, David N. Keys, David May, and Laurie Weisberg), ratify TAAD, LLP as independent auditors for the fiscal year ending December 31, 2026, and approve securities purchase agreements with institutional investors from 2025-2026 involving issuance of common stock equal to 20% or more of outstanding shares. As of the record date May 5, 2026, 25,121,895 shares of common stock were issued and outstanding. The Board unanimously recommends voting 'FOR' all proposals; no financial performance metrics or period-over-period comparisons are detailed in the provided content.

• ·Record Date: May 5, 2026
• ·Annual Meeting virtual registration opens June 16, 2026, at 11:45 A.M. Pacific Time at www.virtualshareholdermeeting.com/SURG2026
• ·Proxies appointed: Kevin Brian Cox and Chelsea Pullano
• ·Proposal 3 involves approval of share issuances to institutional investors equal to 20% or more of outstanding common stock (non-routine matter requiring shareholder approval)

07-05-2026

VAALCO Energy reported a Q1 2026 net loss of $93.8 million ($0.90 per diluted share), driven by $94.2 million in derivative losses and exploration expenses, with Adjusted EBITDAX declining to $11.6 million from $42.9 million in Q4 2025 and $57.0 million in Q1 2025 amid lower sales volumes of 1,094 MBOE (-36% QoQ and YoY) due to Gabon lifting timing, Côte d’Ivoire shut-in, and Canadian asset divestiture. Production averaged 15,110 NRI BOEPD, slightly above guidance midpoint, supported by successful Gabon drilling including Etame 14H at 4,850 gross BOPD and Etame 15H at 2,000 gross BOPD, while capex reached $78.1 million. Guidance was raised for Q2 sales to 16,800-18,300 NRI BOPD (+44% at midpoint QoQ) and FY2026 production/sales by 8%/12% at midpoint, with Côte d’Ivoire restart on track for Q2.

• ·Egypt trade receivables reduced from $31.6 million (Dec 31, 2025) to $24.2 million (Mar 31, 2026).
• ·Quarterly cash dividend of $0.0625 per share payable June 26, 2026.
• ·Confirmed as operator with 60% WI in Kossipo field on CI-40 Block; FDP expected H2 2026.
• ·Baobab Ivoirien FPSO fully moored; production resumption on track for Q2 2026.
• ·Canadian properties divested February 19, 2026, producing ~1,850 BOEPD at sale.
• ·Exploration expense $22.4 million in Q1 2026, up 273% QoQ.

07-05-2026

Bar Harbor Bankshares filed an 8-K on May 07, 2026, reporting Item 5.07: Submission of Matters to a Vote of Security Holders. No specific matters voted on, vote outcomes, numerical results, or other details such as for/against/abstain shares are disclosed in the provided filing information. This is a standard mandatory disclosure following a shareholder meeting, with no financial or operational metrics mentioned.

07-05-2026

07-05-2026

07-05-2026

07-05-2026

07-05-2026

07-05-2026

07-05-2026

07-05-2026

07-05-2026

07-05-2026

Aspen Aerogels reported Q1 2026 total revenue of $37.9 million, down 52% YoY from $78.7 million, driven by Thermal Barrier segment revenue falling 67% to $16.3 million due to reduced demand from regulatory changes, and Energy Industrial segment declining 28% to $21.6 million. Net loss improved to $23.7 million from $301.2 million YoY, though adjusted net loss widened to $23.3 million from $4.8 million; cash balance rose to $175.6 million from $158.6 million year-end 2025, bolstered by a $37.6 million GM settlement. The East Providence facility is set for staged restart in May post-explosion, with a new subsea pipeline award for Q3 2026 delivery and Q2 revenue outlook of $40-48 million.

• ·Q1 2026 Adjusted EBITDA: $(12.7) million vs $4.9 million in Q1 2025
• ·Q1 2026 net loss per share: $0.29 (adjusted $0.28) vs Q1 2025 $3.67 (adjusted $0.06)
• ·Q2 2026 outlook: Net loss $14-20 million ($0.17-0.24 per share), Adjusted EBITDA $(4)-(10) million
• ·FY 2026 Capital Expenditures: less than $10 million
• ·Explosion at East Providence facility on April 8, 2026
• ·Conference call on May 7, 2026 at 8:30 a.m. EST

07-05-2026

Generate Biomedicines reported Q1 2026 financial results with cash, cash equivalents, and marketable securities of $516.6 million as of March 31, 2026, up significantly from $221.5 million at December 31, 2025, driven by $369.3 million in net IPO proceeds completed on March 2, 2026. The company advanced its clinical pipeline, including ongoing Phase 3 SOLAIRIA-1 and SOLAIRIA-2 trials for GB-0895 in severe asthma, site activation for GB-4362 (FDA Fast Track), and planned first dosing for GB-5267 in H2 2026. However, collaboration revenue declined 18% YoY to $7.2 million from $8.8 million, R&D expenses increased 24% to $57.8 million, G&A rose 34% to $13.5 million, and net loss widened to $61.7 million from $44.3 million.

• ·Existing cash sufficient to fund operations into first half of 2028; expects to require additional capital for long-term operations
• ·Non-cash stock-based compensation expense of $6.4 million in Q1 2026 vs $4.7 million in Q1 2025
• ·Total assets $625.7 million as of March 31, 2026 vs $330.2 million as of December 31, 2025

07-05-2026

First Advantage reported record Q1 2026 revenues of $385.2 million, up 8.6% YoY from $354.6 million, with Adjusted EBITDA rising 14.3% to $105.3 million (27.3% margin) and Adjusted Net Income up 48.0% to $45.1 million. GAAP net income improved to $2.2 million (0.6% margin) from a $41.2 million loss in Q1 2025, though the margin remains modest. The company repurchased $19.5 million in shares during the quarter (plus $13.8 million subsequently) and made voluntary debt prepayments totaling $50 million early in 2026, while reaffirming full-year guidance.

• ·Customer retention rate of 97%.
• ·Share repurchase program authorization of $100 million.
• ·Positive momentum in retail & e-commerce, transportation & logistics, and gig economy verticals.
• ·Conference call held on May 7, 2026, at 8:30 a.m. ET.

07-05-2026

InMed Pharmaceuticals Inc. (INM) filed an 8-K on May 7, 2026, disclosing under Regulation FD its financial results for Q3 fiscal year 2026, ended March 31, 2026. The results are detailed in furnished Exhibit 99.1, a news release dated May 6, 2026. No specific financial metrics or performance changes are provided in the filing body.

• ·Filing intended to satisfy Regulation FD obligations; information in Item 7.01 and Exhibit 99.1 is furnished, not filed.
• ·Registrant is an emerging growth company.

07-05-2026

On April 30, 2026, Grayscale Investments Sponsors, LLC, the manager of Grayscale CoinDesk Crypto 5 ETF (GDLC), completed its quarterly portfolio rebalancing in accordance with the CoinDesk 5 Index Methodology, with no new tokens added or removed, maintaining Bitcoin, Ethereum (Ether), XRP, Solana (SOL), and BNB as components. As of May 1, 2026, post-rebalancing weights are 75.99% Bitcoin, 13.47% Ether, 4.16% XRP, 4.04% BNB, and 2.34% SOL. This routine rebalancing adjusts holdings to match index weightings, with additional details in periodic SEC filings.

• ·Each Fund Share represents 0.0003 Bitcoin, 0.0021 Ether, 1.0505 XRP, 0.0023 BNB, and 0.0098 SOL as of May 1, 2026.
• ·Index rebalanced quarterly, beginning 30 days before the last business day of January, April, July, and October.
• ·Annual Report on Form 10-K filed September 5, 2025.

07-05-2026

On May 5, 2026, Fruci & Associates II, PLLC resigned as Quest Water Global, Inc.'s independent accountant at the company's request, with no replacement engaged yet. Prior audit reports for fiscal years ended December 31, 2024 and 2023 contained no adverse opinions or disagreements but noted substantial doubt about the company's ability to continue as a going concern and ongoing material weaknesses in internal control over financial reporting. The board, acting as audit committee, approved the change, and Fruci's concurring letter is filed as Exhibit 16.1.

• ·Resignation effective May 5, 2026; Form 8-K filed May 7, 2026 under Items 4.01 and 9.01.
• ·No disagreements on accounting principles, practices, disclosure, or auditing scope during FY 2023, 2024, and interim through May 5, 2026.
• ·No reportable events except discussions on material weaknesses in internal controls.

07-05-2026

Faraday Future announced plans to upgrade the FX Super One MPV to a more competitive 800V BEV or accelerate the AIHER hybrid project, pausing the original 400V cooperation and potentially delaying mass-production deliveries until strategic financing is secured. The company has shipped 68 EAI robots as of April 30, 2026, achieving positive gross margins, with May shipments accelerating toward a first-quarter target of 200 units and cumulative 2026 shipments exceeding 1,000 units, supported by $45M in recent financing. This strategic shift prioritizes robotics ramp-up to reduce near-term cash outflows and financial risk, but underscores dependency on future funding and execution challenges.

• ·Super One 800V BEV delivery timeline post-funding: first phase 6-9 months, second 12-15 months, third 21-24 months
• ·AIHER hybrid delivery timeline post-funding: first phase 9-12 months, second 21-24 months, third 24-28 months
• ·Press release dated May 5, 2026; SEC filing May 7, 2026

07-05-2026

For Q1 2026, Invesco DB Base Metals Fund reported total assets of $298.7M and shareholders' equity of $290.8M, up 47% and 44% QoQ respectively from $202.8M and $202.5M at year-end 2025, driven by net share purchases of 3.55M shares increasing outstanding shares to 12.4M; NAV per share rose 2.5% QoQ to $23.45. However, net income declined 76% YoY to $0.5M from $2.1M in Q1 2025, due to a $14.8M unrealized loss on commodity futures contracts offsetting $13.5M realized gains.

• ·Unrealized depreciation on LME Commodity Futures Contracts: $4.3M as of March 31, 2026 (up from $0.2M at Dec 31, 2025)
• ·Net realized gain on Commodity Futures Contracts Q1 2026: $13.5M (vs loss of $0.1M in Q1 2025)
• ·Net change in unrealized loss on Commodity Futures Contracts Q1 2026: -$14.8M (vs gain of $1.2M in Q1 2025)
• ·Total notional value of open commodity futures contracts: $290.8M as of March 31, 2026

07-05-2026

ACADIA Pharmaceuticals reported Q1 2026 total revenues of $268,062 thousand, up 9.7% YoY from $244,317 thousand, driven by strong 19.5% growth in DAYBUE to $101,138 thousand while NUPLAZID increased modestly 4.5% to $166,924 thousand. However, SG&A expenses surged 35.3% to $171,019 thousand, resulting in an operating loss of $4,616 thousand versus $19,290 thousand profit YoY and net income declining 80.8% to $3,637 thousand. Cash and cash equivalents rose to $282,212 thousand from $177,695 thousand at December 31, 2025, with net cash from operations at $33,981 thousand, up from $20,323 thousand YoY.

• ·Net cash provided by operating activities $33,981 thousand in Q1 2026, up from $20,323 thousand YoY.
• ·Investment securities decreased to $569,246 thousand at March 31, 2026 from $641,991 thousand at December 31, 2025.
• ·R&D expenses slightly declined 1.8% YoY to $76,868 thousand.
• ·Weighted average diluted shares outstanding 172,706 thousand in Q1 2026.

07-05-2026

For the quarter ended March 31, 2026, INVESCO DB US DOLLAR INDEX BEARISH FUND (UDN) reported total assets of $143,173,914, up from $138,658,061 at December 31, 2025, driven by net share purchases increasing outstanding shares to 7,950,000 from 7,600,000; however, net asset value per share declined to $18.00 from $18.23. The fund posted a net loss of $2,331,514 for Q1 2026 versus a $2,323,750 profit in Q1 2025, due to realized and unrealized losses on short currency futures contracts totaling $3,349,940, despite net investment income rising to $1,018,426 from $472,273 YoY. Affiliated investments grew to $138,814,329 from $131,445,615 QoQ.

• ·Net cash used in operating activities: $6,845,387 for Q1 2026 vs $15,803,005 used in Q1 2025.
• ·Proceeds from share purchases: $24,016,381 in Q1 2026; redemptions: $17,170,994.
• ·Notional value of short futures contracts: $(142,056,816) expiring June 2026.

07-05-2026

Total assets grew 40% QoQ to $1,716,538,920 as of March 31, 2026 from $1,226,515,325 at December 31, 2025, with shareholders' equity increasing 38% to $1,689,908,146 and NAV per share rising 29% to $28.91. Net income surged 432% YoY to $367,798,737 for Q1 2026 versus $69,170,692 in Q1 2025, driven by $183,721,781 realized gains and $175,396,128 unrealized gains on commodity futures contracts; however, total income declined 16% YoY to $11,712,992 and net investment income fell 21% to $8,884,778. While many futures positions appreciated significantly (e.g., ICE-UK Brent Crude +$54.1M), others showed depreciation including NYMEX Natural Gas (-$12,598,582) and ICE Cocoa (-$7,859,083).

• ·Shares outstanding increased by 3,850,000 QoQ to 58,450,000.
• ·Affiliated investments at value: $1,539,988,156 (March 31, 2026) vs $952,402,892 (December 31, 2025).
• ·Net cash used in operating activities: $(101,005,981) for Q1 2026.
• ·Unrealized depreciation on specific futures: ICE Cocoa (-$7,859,083), ICE Coffee (-$3,740,846), NYMEX Natural Gas (-$12,598,582), LME Copper (-$2,193,107).

07-05-2026

For Q1 2026, Invesco DB US Dollar Index Bullish Fund (UUP) reported total assets of $576,443,237 and shareholders' equity of $572,797,660, up significantly from $230,211,749 and $230,068,908 at Dec 31, 2025, driven by net share purchases of 12,100,000 shares raising $334,012,086. The fund swung to net income of $8,716,666 from a Q1 2025 loss of $(12,977,227), boosted by $6,608,538 in net realized/unrealized gains on currency futures; however, total income fell to $2,611,139 from $4,577,831 YoY while net investment income declined to $2,108,128 from $3,809,682. NAV per share rose slightly to $27.81 from $27.07 QoQ (+2.7%).

• ·Open long futures contracts: 5,739 ICE U.S. Dollar Index expiring June 2026 with notional value $572,516,901 and unrealized appreciation $2,988,613.
• ·Net cash from operating activities Q1 2026: $(334,012,086) due to affiliated investment purchases.
• ·Dividend income from affiliates Q1 2026: $2,541,590.

07-05-2026

Reliance Global Group, Inc. held its 2026 Annual Meeting of Stockholders on May 6, 2026, with 9,591,634 shares present or by proxy, representing 45.13% quorum of 21,253,013 outstanding shares. All proposals passed: five directors elected (Ezra Beyman, Alex Blumenfrucht, Scott Korman, Ben Fruchtzweig, Sheldon Brickman), ratification of Urish Popeck & Co., LLC as auditors, amendment to increase 2025 Equity Incentive Plan shares by 14,000,000 to 16,000,000 total, and approval of share issuance under Nasdaq Rule 5635(d). However, Proposals 3 and 4 saw notable opposition (789,931 and 717,894 votes against, respectively) and high broker non-votes (5,902,355 across director elections and other proposals).

• ·Proposal 2 (auditor ratification): 9,156,532 For, 105,481 Against, 329,621 Abstained.
• ·Proposal 3 (Equity Plan amendment): 2,780,312 For, 789,931 Against, 119,036 Abstained.
• ·Proposal 4 (Share issuance): 2,865,554 For, 717,894 Against, 105,831 Abstained.
• ·Director elections: Votes For ranged 3,275,234 to 3,409,300; Abstained 279,979 to 414,045.

07-05-2026

Amplitude, Inc. reported Q1 2026 revenue of $93,492, up 16.9% YoY from $79,953, driven by growth in both US ($56,689, +16.6%) and international ($36,803, +17.5%) segments, with gross profit rising 14.3% to $68,283. However, net loss widened slightly to $23,274 from $22,231 YoY due to higher operating expenses (up 10.1% to $92,423), particularly sales and marketing (up 15.1% to $50,803), while total assets declined QoQ to $401,742 from $420,684 and cash from operations remained negative at $11,609.

• ·Accounts receivable increased to $40,899 as of March 31, 2026 from $23,423 as of December 31, 2025.
• ·Marketable securities decreased to $95,335 current and $31,544 non-current as of March 31, 2026 from $110,882 and $60,543 as of December 31, 2025.
• ·Stock-based compensation expense was $19,962 in Q1 2026, down slightly from $20,597 in Q1 2025.
• ·Company repurchased 2,755 shares of common stock for $20,728 in Q1 2026.

07-05-2026

Pattern Group Inc. reported strong Q1 2026 results with revenues surging 43% YoY to $773,727 thousand from $540,406 thousand, fueled by growth across all channels including Amazon.com (+36%), other online marketplaces (+109%), and SaaS/logistics (+173%); net income rose 28% to $29,213 thousand, and operating cash flow increased 50% to $72,581 thousand. However, diluted EPS edged down to $0.16 from $0.17, accounts receivable declined to $141,279 thousand from $177,214 thousand at year-end, inventory changes swung to an increase, and the company incurred higher investing outflows of $9,263 thousand along with $8,256 thousand in financing outflows from stock repurchases and tax withholdings.

• ·Unrealized loss on foreign currency translation worsened to $(205) thousand from $(8) thousand YoY.
• ·Total stockholders' equity increased to $609,688 thousand from $580,995 thousand at December 31, 2025.
• ·No preferred stock dividends in 2026 vs. $4,436 thousand undeclared Series B dividend in 2025.
• ·Stock-based compensation expense of $7,941 thousand recognized in Q1 2026.

07-05-2026

Armata Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to AP-SA02, the company's intravenously administered Staphylococcus aureus multi-phage product candidate. This designation is for the adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus or methicillin-resistant S. aureus. The announcement was made via press release on May 7, 2026.

07-05-2026

WaterBridge Infrastructure LLC reported total revenues of $200,977 for Q1 2026, up 105% YoY from $97,910, primarily driven by produced water handling revenues surging 114% to $181,937, while operating income rose 94% to $30,456 and net income attributable to the company increased to $3,515. However, water solutions revenues declined 23% YoY to $9,014 from $11,658, cash and equivalents dipped 2% QoQ to $50,668, and capital expenditures more than doubled to $110,940 amid total assets growth of just 1% QoQ to $3,752,471.

• ·Net cash provided by operating activities increased to $95,103 in Q1 2026 from $43,212 YoY.
• ·Long-term debt increased to $1,457,378 as of March 31, 2026 from $1,431,837 at year-end.
• ·Class A shares issued and outstanding rose to 47,016,059 from 43,264,850 QoQ due to RSU vesting and redemptions.

07-05-2026

For Q1 2026, BBSI reported total revenues of $307,005 up 4.9% YoY from $292,566, driven by 6.6% growth in professional employer services to $292,997, though staffing services declined 20.6% to $14,008. Gross margin improved slightly 1.3% to $43,185, but higher SG&A expenses up 5.9% to $47,480 contributed to a widened operating loss of $6,468 and net loss of $14,803 versus $1,021 in Q1 2025. Cash used in operations surged to $22,078 from cash provided of $5,211 YoY, with significant stock repurchases of $20,285.

• ·Company repurchased 701 shares for $20,285 in Q1 2026 vs 229 shares for $9,160 in Q1 2025.
• ·Paid cash dividends of $1,979 ($0.08 per share) in Q1 2026.
• ·Restricted cash and investments totaled $216,920 as of Mar 31 2026 (current $123,119 + long-term $93,801).
• ·Basic loss per share $0.59 in Q1 2026 vs $0.04 in Q1 2025.

07-05-2026

Net assets for Bitwise 10 Crypto Index ETF declined 34.2% QoQ to $678,236 as of March 31, 2026 from $1,029,869 at December 31, 2025, driven by significant unrealized depreciation of $308,386 in crypto assets and $111,485 in redemption outflows, resulting in a NAV per share drop to $44.62 from $59.01. While the net decrease in net assets from operations improved slightly YoY to $(240,148) from $(255,642) with realized gains rising to $69,785 from $8,866, unrealized losses worsened and shares outstanding fell 12.9% to 15,201,947 due to 2,250,000 shares redeemed. Crypto holdings across BTC, ETH, and others saw sharp fair value declines QoQ.

• ·Management fees payable decreased to $447 from $1,217 QoQ.
• ·Cash position minimal at $6 as of March 31, 2026 vs $15 at December 31, 2025.
• ·Net cash provided by operating activities $128,544 for Q1 2026 vs used $(76) in Q1 2025.

07-05-2026

LandBridge Co LLC reported Q1 2026 total revenues of $51,005 thousand, up 16% YoY from $43,951 thousand, with strong growth in easements and other surface-related revenues (+80% to $11,600 thousand) and related party surface use royalties (+60% to $11,041 thousand). However, resource sales declined 27% YoY to $5,225 thousand, oil and gas royalties fell 12% to $2,972 thousand, and related party resource royalties dropped 55% to $1,274 thousand. Net income increased 16% to $17,868 thousand, operating cash flow surged to $41,120 thousand from $15,913 thousand, while total debt decreased QoQ to $535,539 thousand and cash slightly declined to $29,679 thousand.

• ·Class A basic EPS $0.31 in Q1 2026, up from $0.27 in Q1 2025.
• ·Weighted average basic Class A shares: 27,838,580 in Q1 2026 vs 23,255,419 in Q1 2025.
• ·Net cash used in investing activities: $2,148 thousand in Q1 2026, improved from $17,867 thousand in Q1 2025.
• ·Dividends and distributions paid: $14,728 thousand in Q1 2026.